Evidence map›Paper›PMID 36588949›Full record

ArticleFrontiers in bioengineering and biotechnology2022

Calcium phosphate-based nanomedicine mediated CRISPR/Cas9 delivery for prostate cancer therapy.

Chao-Gang Wei, Rui Zhang, Lan-Yi Wei, Peng Pan, He Zu, Ya-Zhen Liu, Yong Wang, Jun-Kang Shen

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in bioengineering and biotechnology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.7field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 9 citations in OpenAlex.

  1. Preparation of Polymeric Nanoparticles for Gene Delivery.Methods in molecular biology (Clifton, N.J.) · 2027
    Article
  2. Review
  3. Review
  4. Review
  5. Review
  6. Review
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Chao-Gang WeiDepartment of Radiology, The Second Affiliated Hospital of Soochow University, Suzhou, China.
Rui ZhangDepartment of Radiology, The Second Affiliated Hospital of Soochow University, Suzhou, China.
Lan-Yi WeiDepartment of Radiology, The Second Affiliated Hospital of Soochow University, Suzhou, China.
Peng PanDepartment of Radiology, The Second Affiliated Hospital of Soochow University, Suzhou, China.
He ZuState Key Laboratory of Radiation Medicine and Protection, School of Radiation Medicine and Protection, School for Radiological and Interdisciplinary Sciences (RAD-X), Collaborative Innovation Center of Radiation Medicine of Jiangsu Higher Education Institutions, Soochow University, Suzhou, China.
Ya-Zhen LiuDepartment of Emergency, The Second Affiliated Hospital of Soochow University, Suzhou, China.
Yong WangState Key Laboratory of Radiation Medicine and Protection, School of Radiation Medicine and Protection, School for Radiological and Interdisciplinary Sciences (RAD-X), Collaborative Innovation Center of Radiation Medicine of Jiangsu Higher Education Institutions, Soochow University, Suzhou, China.
Jun-Kang ShenDepartment of Radiology, The Second Affiliated Hospital of Soochow University, Suzhou, China.
Soochow University · CNSecond Affiliated Hospital of Soochow University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

castration-resistance prostate cancerCRISPR/Cas9EphA2nanomedicinenon-viral carriertarget delivery

Identifiers

PMID36588949
PMCPMC9794984
OpenAlexW4311356950

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.